Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mirum Pharmaceuticals Inc MIRM

Healthcare Biotechnology
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally... see more

Recent & Breaking News (NDAQ:MIRM)

Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Business Wire March 12, 2020

Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

Business Wire February 18, 2020

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

PR Newswire January 16, 2020

Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

Business Wire January 14, 2020

Mirum Pharmaceuticals Announces Pricing of Public Offering

Business Wire January 8, 2020

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

Business Wire December 16, 2019

Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast

Business Wire December 13, 2019

Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

Business Wire November 25, 2019

Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

Business Wire November 8, 2019

Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

Business Wire November 6, 2019

Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer

Business Wire October 28, 2019

Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome

Business Wire October 28, 2019

Durability of Treatment Effect of Mirum Pharmaceuticals' Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019

Business Wire October 21, 2019

Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

Business Wire October 1, 2019

Company Profile for Mirum Pharmaceuticals

Business Wire September 26, 2019

Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

Business Wire September 26, 2019

Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

Business Wire August 28, 2019